The movement is gaining momentum with Florida citizens, law enforcement and politicians without regard for partisanship all coming together toward a common goal of providing the best available treatments for patients.
Sarasota, FL (PRWEB) January 28, 2015
AltMed, the Florida company that brings pharmaceutical industry precision to the development and production of medical cannabis, is praising and supporting Republican Sen. Jeff Brandes and other leaders who realize the urgency to act sooner than later to help Florida patients in need.
SB-528 addresses the concerns that prevented Amendment-2 from reaching the 60-percent vote required to pass. 57.6% of Floridians voted in favor of legalizing medical marijuana, receiving more votes than any other statewide candidate. SB-528 also expands on the patient reach of the current limited high-CBD law (Senate Bill SB-1030) to include the following specific conditions: cancer, HIV, AIDS, epilepsy, ALS, MS, Crohn’s and Parkinson’s.
"In SB-528, Sen. Brandes has acknowledged the importance of including additional patients who can realize the benefits of the best available treatments," said David Wright, CEO of AltMed. "We commend Sen. Brandes for taking this important step forward for Florida patients."
AltMed additionally applauds the 2014 Florida Legislature for passing SB-1030 which was a significant acknowledgement by the Senate, House and Governor of the benefits of marijuana as a medicine to treat Florida patients.
"We are extremely impressed that leaders in the Senate, House and Governor's office have already taken the position of understanding the need to provide Florida citizens with treatments that will benefit them by supporting SB-1030."
AltMed is equally encouraged by the number of Sheriff's across the state who are becoming proactive in the movement to ensure Florida quickly creates acceptable standards and language so that beneficial treatments can be made available to patients.
"The movement is gaining momentum with Florida citizens, law enforcement and politicians without regard for partisanship all coming together toward a common goal of providing the best available treatments for patients," added Wright.
AltMed is working to support the goal of achieving legislative passage of SB-528 by the end of the 2015 session (Friday May 1).
AltMed LLC is a fully integrated company that will bring pharmaceutical industry precision to the development, production and dispensing of medical cannabis. Established in early 2014 by a consortium of Sarasota residents, AltMed's Executive Chairman and its CEO are both former senior pharmaceutical executives. Their previous company, MedImmune (acquired by Astra Zeneca in 2007), produces a drug for the prevention of respiratory infections in infants. AltMed is participating in a competitive licensure process to become one of five Florida licensees to be selected to grow and dispense medical cannabis under the Compassionate Medical Cannabis Act of 2014.